tirzepatide initial dose What is the Starting for Weight Loss? Tirzepatide dosing guide with chart

Start Online Visit

This approval significantly expands access to effective treatment, offering a needle-free alternative for patients seeking to improve their metabolic health and achieve long-term weight reduction

Patients included in the trial had HbA1c 7-10% and were treated with either diet and exercise alone, or any oral anti-hyperglycemic agent except dipeptidyl peptidase-4 (DPP-4) inhibitors or GLP-1 receptor agonists

Other significant considerations include: Injection site reactions (for subcutaneous formulations) Hypoglycaemia risk (particularly if used alongside other glucose-lowering medications) Pancreatitis (rare but serious) Gallbladder disease (including gallstones and cholecystitis) Dehydration leading to acute kidney injury (particularly with severe gastrointestinal side effects) Diabetic retinopathy complications (particularly noted with semaglutide in diabetes patients) Potential thyroid effects (medullary thyroid carcinoma risk in animal studies, though human relevance remains unclear) A Parkinson's-specific concern is that GLP-1 receptor agonists delay gastric emptying, which may further impair levodopa absorption and potentially worsen motor fluctuations or 'OFF' periods in patients on this medication

The irony of tirzepatide is that the medication becomes so effective at suppressing appetite that it can actually create nutritional problems